Climb Bio, Inc. (CLYM)
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Climb Bio, Inc.
NASDAQ:CLYMHealthcare · Biotechnology
-0.77%$10.25
AH$10.25+0.00%vs close
Mkt Cap$588.72M
Float38.28M
O/S57.44M
Vol
$ Vol
RVOL
Inst Own98.2%
SI25.6%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$59.85M
Total Assets$167.74M
Free Cash Flow-$54.54M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$541K
Total Equity$160.47M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in CLYM's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$167.74M
Liabilities$7.27M
Accounts Receivable$0
Accounts Payable$2.27M
Inventory$0
PP&E (Net)$793K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $97K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | -$97K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $46.62M | $14.34M | $15.41M | $26.21M | $23.32M | $9.34M | $4.02M |
| Selling, General, and Administrative | $21.17M | $16.02M | $24.86M | $18.92M | $12.35M | $2.42M | $677K |
| Other | $0 | $51.66M | $0 | $0 | $0 | $9.16M | $2.75M |
| Total Operating Expenses | $67.79M | $82.02M | $40.27M | $45.13M | $35.67M | $20.93M | $7.45M |
| Operating Income (EBIT) | -$67.88M | -$82.02M | -$40.27M | -$45.13M | -$35.67M | -$20.93M | -$7.45M |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $8.32M | $8.13M | $4.62M | $1.38M | $0 | $0 | $0 |
| Other Income (Expense) | $8.03M | $8.12M | $5.16M | -$109K | -$11.81M | $257K | $899K |
| Income Before Tax (EBT) | -$59.85M | -$73.9M | -$35.12M | -$45.24M | -$47.48M | -$20.67M | -$6.55M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$59.85M | -$73.9M | -$35.12M | -$45.24M | -$47.48M | -$20.67M | -$6.55M |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | -1.97 | -0.56 |
| Diluted EPS | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | -1.97 | -0.56 |
| Weighted Average OS | 67.81M | 48.16M | 26.99M | 26.31M | 12.26M | 11.66M | 11.66M |
| EBITDA | -$59.75M | -$30.36M | -$35.12M | -$45.24M | -$47.48M | -$11.77M | -$4.7M |
| EBITDA Margin | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $35.69M | $87.23M | $93.11M | $43.59M | $46.92M | $20.49M | $21.22M |
| Short-Term Investments | $65.39M | $63.69M | $13.69M | $79.98M | $89.56M | $0 | $0 |
| Cash and Short-Term Investments | $101.08M | $150.92M | $106.8M | $123.57M | $136.48M | $20.49M | $21.22M |
| Accounts Receivable | $0 | $1.12M | $2.46M | $6.49M | $6.52M | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $4.77M | $256K | $112K | $3M | $852K | $11K | $35K |
| Total Current Assets | $105.85M | $154.87M | $110.25M | $134.39M | $148.25M | $22M | $21.28M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $793K | $490K | $199K | $471K | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $59.57M | $61.61M | $0 | $0 | $24.92M | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.53M | $215K | $15K | $128K | $70K | $2.63M | $112K |
| Total Long-Term Assets | $61.89M | $62.31M | $214K | $599K | $24.99M | $2.63M | $112K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $167.74M | $217.19M | $110.47M | $134.99M | $173.24M | $24.63M | $21.39M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $2.27M | $705K | $66K | $750K | $1.4M | $1.09M | $647K |
| Short-Term Debt | $256K | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $2.57M | $31K | $138K | $0 | $0 | $551K | $0 |
| Total Current Liabilities | $6.98M | $4.93M | $2.83M | $6.1M | $6.03M | $3.06M | $783K |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $22K | $0 | $7K | $0 | $0 |
| Total Long-Term Liabilities | $285K | $375K | $37K | $180K | $7K | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $7.27M | $5.31M | $2.87M | $6.28M | $6.04M | $3.06M | $783K |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $46.55M | $26.17M |
| Common Stock | $5K | $7K | $3K | $3K | $3K | $1K | $1K |
| Retained Earnings | -$289.73M | -$229.88M | -$155.98M | -$120.86M | -$75.62M | -$28.14M | -$7.47M |
| Comprehensive Income & Other | $435K | $23K | -$2K | -$358K | -$123K | $0 | $0 |
| Other Stockholders' Equity | $450.2M | $441.75M | $263.57M | $249.57M | $242.82M | $49.7M | $28.08M |
| Total Equity | $160.47M | $211.88M | $107.6M | $128.72M | $167.2M | $21.57M | $20.61M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $167.74M | $217.19M | $110.47M | $134.99M | $173.24M | $24.63M | $21.39M |
| Supplementary Data | |||||||
| Total Debt | $541K | $532K | $349K | $480K | $0 | $0 | $0 |
| Net Debt | -$35.14M | -$86.7M | -$92.76M | -$43.1M | -$46.92M | -$20.49M | -$21.22M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$59.85M | -$73.9M | -$35.12M | -$45.24M | -$47.48M | -$20.67M | -$6.55M |
| Depreciation & Amortization | $97K | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $8.05M | $5.56M | $12.81M | $6.99M | $3.74M | $707K | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $1.56M | -$1.14M | -$686K | -$653K | $318K | -$24K | $17K |
| Other Working Capital | -$2.17M | $2.84M | $4.45M | $863K | -$4.49M | -$2.91M | -$326K |
| Total Working Capital Change | -$601K | $1.7M | $3.76M | $210K | -$4.17M | -$2.94M | -$309K |
| Other Non-Cash Items | -$2.06M | $51.08M | -$2.05M | $674K | $11.84M | $8.8M | $1.85M |
| Net Cash from Operating | -$54.36M | -$15.56M | -$20.6M | -$37.37M | -$36.07M | -$14.1M | -$5.01M |
| Investing Activities | |||||||
| Capital Expenditures | -$186K | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$108.08M | -$132.2M | -$58.45M | -$87.96M | -$114.97M | $0 | $0 |
| Sales of Investments | $111.1M | $20.75M | $127.43M | $122.4M | $0 | $0 | $0 |
| Other Investing Activities | $0 | -$9.64M | $0 | $0 | $0 | $8.08M | $0 |
| Net Cash from Investing | $2.83M | -$121.09M | $68.98M | $34.44M | -$114.97M | $8.08M | $0 |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | - | - |
| Common Stock Issuance | -$21K | $119.75M | $841K | $0 | $83.14M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $10.98M | $0 | $0 | $149K | $0 | $0 |
| Net Cash from Financing | -$21K | $130.73M | $841K | $0 | $177.23M | $4.92M | $26.24M |
| Forex Effect | $0 | $42K | $304K | -$408K | $245K | $359K | -$12K |
| Net Change in Cash | -$51.54M | -$5.88M | $49.53M | -$3.34M | $26.43M | -$736K | $21.22M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$54.36M | -$15.56M | -$20.6M | -$37.37M | -$36.07M | -$14.1M | -$5.01M |
| Capital Expenditure | -$186K | $0 | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$54.54M | -$15.56M | -$20.6M | -$37.37M | -$36.07M | -$14.1M | -$5.01M |
| Cash at Beginning | $87.23M | $93.11M | $43.59M | $46.92M | $20.49M | $21.22M | $0 |
| Cash at End | $35.69M | $87.23M | $93.11M | $43.59M | $46.92M | $20.49M | $21.22M |